Predictive Accuracy of a Polygenic Risk Score for Postoperative Atrial Fibrillation After Cardiac Surgery.


Journal

Circulation. Genomic and precision medicine
ISSN: 2574-8300
Titre abrégé: Circ Genom Precis Med
Pays: United States
ID NLM: 101714113

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 2 3 2021
medline: 4 1 2022
entrez: 1 3 2021
Statut: ppublish

Résumé

Postoperative atrial fibrillation (PoAF) remains a significant risk factor for increased morbidity and mortality after cardiac surgery. The ability to accurately identify patients at risk through clinical risk factors is limited. There is growing evidence that polygenic risk contributes significantly to PoAF and incorporating measures of genetic risk could enhance prediction. A retrospective cohort study of 1047 patients of White European ancestry who underwent either coronary artery bypass grafting or valve surgery at a tertiary academic center and were free from a history or persistent preoperative atrial fibrillation. The primary outcome was defined as PoAF based on postoperative ECG reports, medical record documentation, and changes in medication. The exposure was a polygenic risk score (PRS) comprising 2746 single-nucleotide polymorphisms previously associated with atrial fibrillation risk. The prediction of PoAF risk was assessed using measures of model discrimination, calibration, and net reclassification improvement. A total of 259 patients (24.7%) developed PoAF. The PRS was significantly associated with a higher risk for PoAF (odds ratio, 1.63 per SD increase in PRS [95% CI, 1.41-1.90]). Addition of PRS to patient- and procedure-related predictors of PoAF significantly increased the C statistic from 0.742 to 0.782 (change in C statistic, 0.040 [95% CI, 0.021-0.060]) while maintaining good calibration. The addition of the PRS to patient- and procedure-related predictors of PoAF improved model fit (likelihood ratio test, The PRS for PoAF was associated with improved discrimination, calibration, and risk reclassification compared with conventional clinical predictors suggesting that a PoAF PRS may enhance risk prediction of PoAF in patients undergoing coronary artery bypass grafting or valve surgery.

Sections du résumé

BACKGROUND
Postoperative atrial fibrillation (PoAF) remains a significant risk factor for increased morbidity and mortality after cardiac surgery. The ability to accurately identify patients at risk through clinical risk factors is limited. There is growing evidence that polygenic risk contributes significantly to PoAF and incorporating measures of genetic risk could enhance prediction.
METHODS
A retrospective cohort study of 1047 patients of White European ancestry who underwent either coronary artery bypass grafting or valve surgery at a tertiary academic center and were free from a history or persistent preoperative atrial fibrillation. The primary outcome was defined as PoAF based on postoperative ECG reports, medical record documentation, and changes in medication. The exposure was a polygenic risk score (PRS) comprising 2746 single-nucleotide polymorphisms previously associated with atrial fibrillation risk. The prediction of PoAF risk was assessed using measures of model discrimination, calibration, and net reclassification improvement.
RESULTS
A total of 259 patients (24.7%) developed PoAF. The PRS was significantly associated with a higher risk for PoAF (odds ratio, 1.63 per SD increase in PRS [95% CI, 1.41-1.90]). Addition of PRS to patient- and procedure-related predictors of PoAF significantly increased the C statistic from 0.742 to 0.782 (change in C statistic, 0.040 [95% CI, 0.021-0.060]) while maintaining good calibration. The addition of the PRS to patient- and procedure-related predictors of PoAF improved model fit (likelihood ratio test,
CONCLUSIONS
The PRS for PoAF was associated with improved discrimination, calibration, and risk reclassification compared with conventional clinical predictors suggesting that a PoAF PRS may enhance risk prediction of PoAF in patients undergoing coronary artery bypass grafting or valve surgery.

Identifiants

pubmed: 33647223
doi: 10.1161/CIRCGEN.120.003269
pmc: PMC8058298
mid: NIHMS1678650
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e003269

Subventions

Organisme : American Heart Association-American Stroke Association
ID : 16FTF30130005
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM130791
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM010685
Pays : United States

Références

Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
Circ Cardiovasc Genet. 2014 Oct;7(5):625-633
pubmed: 25049040
Eur J Epidemiol. 2011 Apr;26(4):261-4
pubmed: 21431839
Circ Cardiovasc Genet. 2009 Oct;2(5):499-506
pubmed: 20031626
Eur Heart J. 2009 Feb;30(4):410-25
pubmed: 19174427
Circ Cardiovasc Genet. 2012 Feb 1;5(1):113-21
pubmed: 22235037
Am Heart J. 2015 Sep;170(3):580-90.e28
pubmed: 26385043
JAMA. 2020 Feb 18;323(7):636-645
pubmed: 32068818
J Am Heart Assoc. 2014 Mar 24;3(2):e000752
pubmed: 24663335
J Am Coll Cardiol. 2014 Apr 1;63(12):1200-1210
pubmed: 24486271
J Cardiothorac Vasc Anesth. 2020 Jan;34(1):20-28
pubmed: 31606278
Circ Res. 2020 Jan 17;126(2):200-209
pubmed: 31691645
Curr Opin Anaesthesiol. 2020 Jun;33(3):463-474
pubmed: 32371636
J Thorac Cardiovasc Surg. 2011 Feb;141(2):559-70
pubmed: 20434173
Circulation. 2017 Apr 4;135(14):1311-1320
pubmed: 27793994
Nat Rev Cardiol. 2019 Jul;16(7):417-436
pubmed: 30792496
Circulation. 2007 Feb 20;115(7):928-35
pubmed: 17309939
J Cardiothorac Surg. 2012 Sep 19;7:87
pubmed: 22992266
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
JAMA. 2004 Apr 14;291(14):1720-9
pubmed: 15082699
Can J Anaesth. 2018 Jul;65(7):786-796
pubmed: 29644515
Genet Med. 2020 Jul;22(7):1191-1200
pubmed: 32296164
Science. 2007 Jun 8;316(5830):1491-3
pubmed: 17478679
Nat Genet. 2017 Jun;49(6):946-952
pubmed: 28416818
Ann Thorac Surg. 2016 Dec;102(6):2018-2026
pubmed: 27424470
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Eur Heart J. 2013 Aug;34(29):2243-51
pubmed: 23444395
Anesth Analg. 2019 Jan;128(1):33-42
pubmed: 30550473
Nat Genet. 2010 Mar;42(3):240-4
pubmed: 20173747
Nat Rev Cardiol. 2013 Jun;10(6):317-29
pubmed: 23591267

Auteurs

Miklos D Kertai (MD)

Departments of Anesthesiology (M.D.K.), Vanderbilt University Medical Center, Nashville, TN.

Jonathan D Mosley (JD)

Medicine (J.D.M., D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

Jing He (J)

Biomedical Informatics (J.H., L.B., D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

Abinaya Ramakrishnan (A)

Vanderbilt University, Nashville, TN (A.R., M.A., Y.H.).

Mark J Abdelmalak (MJ)

Vanderbilt University, Nashville, TN (A.R., M.A., Y.H.).

Yurim Hong (Y)

Vanderbilt University, Nashville, TN (A.R., M.A., Y.H.).

M Benjamin Shoemaker (MB)

Division of Cardiovascular Medicine, Nashville VA Medical Center and Vanderbilt University, TN (M.B.S.).

Dan M Roden (DM)

Medicine (J.D.M., D.M.R.), Vanderbilt University Medical Center, Nashville, TN.
Biomedical Informatics (J.H., L.B., D.M.R.), Vanderbilt University Medical Center, Nashville, TN.
Pharmacology (D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

Lisa Bastarache (L)

Biomedical Informatics (J.H., L.B., D.M.R.), Vanderbilt University Medical Center, Nashville, TN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH